Dipcan is the official App of the Dipcan Studio, a project that has
as objective the generation of an Artificial Intelligence algorithm
that will integrate clinical, radiomic, anatomopathological and
Genetics of 2,000 patients with metastatic cancer. In turn, the
study will allow participating patients to have a
better knowledge of your oncological disease.
Through this App, patients will have access to the results of
the tests carried out throughout the study. These results will be
confidential, however, the user may consult them with their
passwords and share them with other doctors or centers if so
deemed accurate, at your own risk.
At the end of the study, the project oncologist will explain to the patient
the findings found in detail and will answer all your questions.
However, patients will continue to see their oncologist for their
routine treatment and check-ups.
Dipcan is an observational research study, so no
administer treatments that improve survival or quality of life
patients' lives. The knowledge gained through it
will try to help the elaboration of health strategies to
diagnose and treat the most cost-effective tumors
prevalent at the population level.
The study begins in 2022 and will end in 2024. Throughout
this time the precise diagnostic tests will be carried out
necessary for the development of the project and the integration of the
data.
The project has European funding within the Next program
Generation EU, granted through the Ministry of Economy and
Digital Transformation, and is led by Eurofins Megalab in
collaboration with the MD Anderson Spain Foundation, Genomcore,
Artelnics, Pangaea Oncology, Quibim and Atrys Health.
The integration of all the clinical, radiomic,
pathological and molecular data obtained from the participants in the
study could help advance the treatment of patients with
metastatic cancer. This information could provide insight
multidimensional cancer in the Spanish population from all
angles. If you participate in Dipcan, you will be helping to build the
medicine of the future!
as objective the generation of an Artificial Intelligence algorithm
that will integrate clinical, radiomic, anatomopathological and
Genetics of 2,000 patients with metastatic cancer. In turn, the
study will allow participating patients to have a
better knowledge of your oncological disease.
Through this App, patients will have access to the results of
the tests carried out throughout the study. These results will be
confidential, however, the user may consult them with their
passwords and share them with other doctors or centers if so
deemed accurate, at your own risk.
At the end of the study, the project oncologist will explain to the patient
the findings found in detail and will answer all your questions.
However, patients will continue to see their oncologist for their
routine treatment and check-ups.
Dipcan is an observational research study, so no
administer treatments that improve survival or quality of life
patients' lives. The knowledge gained through it
will try to help the elaboration of health strategies to
diagnose and treat the most cost-effective tumors
prevalent at the population level.
The study begins in 2022 and will end in 2024. Throughout
this time the precise diagnostic tests will be carried out
necessary for the development of the project and the integration of the
data.
The project has European funding within the Next program
Generation EU, granted through the Ministry of Economy and
Digital Transformation, and is led by Eurofins Megalab in
collaboration with the MD Anderson Spain Foundation, Genomcore,
Artelnics, Pangaea Oncology, Quibim and Atrys Health.
The integration of all the clinical, radiomic,
pathological and molecular data obtained from the participants in the
study could help advance the treatment of patients with
metastatic cancer. This information could provide insight
multidimensional cancer in the Spanish population from all
angles. If you participate in Dipcan, you will be helping to build the
medicine of the future!
Show More
